NTM-001
Moderately-severe acute pain (e.g., post-surgical)
Late Stage (assumed Phase 3-ready)Active
Key Facts
Indication
Moderately-severe acute pain (e.g., post-surgical)
Phase
Late Stage (assumed Phase 3-ready)
Status
Active
Company
About Neumentum
Neumentum is a private, pre-revenue biotech focused on transforming pain treatment through a pipeline of non-opioid analgesics. Its lead assets include NTM-001, a late-stage, novel formulation of ketorolac for continuous infusion, and NTM-006, a novel oral compound with a new mechanism of action. The company is targeting a massive market driven by the opioid crisis and the critical need for effective, safer pain management alternatives, led by an experienced team with deep expertise in pain drug development and commercialization.
View full company profile